Fig. 7: Inhibition of DLK/LZK and GCK-IV pathways protects against neuronal injury. | npj Regenerative Medicine

Fig. 7: Inhibition of DLK/LZK and GCK-IV pathways protects against neuronal injury.

From: Human retinal ganglion cell neurons generated by synchronous BMP inhibition and transcription factor mediated reprogramming

Fig. 7

a Diagram illustrating a model for blocking DLK-induced cell death. b Timeline for RGC-iN differentiation, colchicine-induced injury and neuroprotection with GNE-3511. c RGC-iNs treated with or without GNE-3511 (1 μM), 72 h after treatment with or without colchicine (40 nM). d Quantification of the CellTiterGlo (CTG) viability assay in the presence or absence of GNE-3511 in combination with increasing doses of colchicine (n = 4). e Timeline for RGC-iN differentiation, injury from paclitaxel(P), and neuroprotection with PF-06260933(PF). f Representative Calcein-AM images after treatment at D1, 2, 3, and 4 with control, paclitaxel, PF-06260933 and paclitaxel + PF-06260933. Quantification of viability using CTG in NAIP2 cells in g IMR90.4, h WA09, and i GM23720 RGC-iNs normalized relative to controls after treatment with P, PF or P + PF (n = 3). Scale c = 200 µm, f = 400 µm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Error bars are reported as standard deviation (SD).

Back to article page